Treovir Announces Positive Results of Phase 1 Study of G207 in Pediatric Patients with Recurrent High-Grade Glioma
2021-04-12 · Treovir, Inc · original treovir.com ↗
New England Journal of Medicine published the Phase 1 trial data on April 10, 2021 in original article entitled “Oncolytic HSV-1 Immunovirotherapy for Pediatric High-Grade Gliomas” G207 alone or in combination with radiation is well tolerated by pediatric patients G207 showed evidence of radiographic, neuropathological, or clinical response in 11 of 12 patients G207 converted immunologically “cold” tumors to “hot” Phase 2 program to launch in 2021 aimed at market approval for G207 Additionally, a presentation of the findings of the Phase I trial was made by Gregory K. Friedman, MD, University of Alabama Birmingham and the Phase 1 G207 clinical trial Principal Investigator, at the annual AACR (American Association for Cancer Research) virtual meeting on April 10, 2021. Treovir Press Release April 12, 2021 Friedman NEJM Article April 10, 2021
The release as fetched from its publisher. treovir.com ↗